BioCentury
ARTICLE | Clinical News

Antegren natalizumab: Phase II

August 2, 1999 7:00 AM UTC

Preliminary results from a 180-patient Phase II trial show the compound is ineffective at treating acute exacerbation in MS patients. The study analyzed patients receiving a single dose of Antegren within 96 hours of the onset of exacerbation. The Kurtzke Expanded Disability Status Scale showed no statistical significance between baseline and one week effect, the primary end point; however, ELN said the compound may have utility in chronic MS since it appears to take 3-4 weeks to reach therapeutic effect. ...